Výpis publikací

BUŠA, Daniel; Zdeňka HERUDKOVÁ; Jan HÝL; Jakub VLAŽNÝ; Filip SOKOL; Květoslava MATULOVÁ; Adam FOLTA; Jakub HYNŠT; Lucy VOJTOVA; Leoš KŘEN; Martin REPKO; Zdeněk RÁČIL; Jiří MAYER a Martin ČULEN. Robust acute myeloid leukemia engraftment in humanized scaffolds using injectable biomaterials and intravenous xenotransplantation. Molecular oncology. HOBOKEN: WILEY, 2025, roč. 19, č. 5, s. 1371-1385. ISSN 1574-7891. Dostupné z: https://doi.org/10.1002/1878-0261.13790.

STYLIANOU, Filio; Adriana LADUNGOVÁ; Jan HÝL; Daniel BUŠA; Martin ČULEN; Barbora WEINBERGEROVÁ; Jiří MAYER a Michal ŠMÍDA. ANALYSIS OF ALTERNATIVE THERAPEUTIC OPTIONS FOR ACUTE MYELOID LEUKEMIA PATIENTS RESISTANT TO VENETOCLAX BASED ON DRUG SCREENING AND EXPRESSION PROFILING. In III. ČESKÝ HEMATOLOGICKÝ A TRANSFUZIOLOGICKÝ SJEZD in Transfuze a Hematologie Dnes. 2024.

HÝL, Jan; V. BUČKOVÁ; T. SLAMENÍKOVÁ; M. ROKYTOVÁ; Jiří MAYER a Martin ČULEN. IN VITRO CULTURE OF ACUTE MYELOID LEUKEMIA: EFFECT OF MEDIA COMPONENTS, SMALL INHIBITORS, AND FEEDER CELLS. In III. ČESKÝ HEMATOLOGICKÝ A TRANSFUZIOLOGICKÝ SJEZD in Transfuze a Hematologie Dnes. 2024.

BUŠA, Daniel; Zdeňka HERUDKOVÁ; Jan HÝL; Jakub VLAŽNÝ; F. SOKOL; Květoslava MATULOVÁ; A. FOLTA; Jakub HYNŠT; Lucy VOJTOVÁ; Leoš KŘEN; Martin REPKO; Zdeněk RÁČIL; Jiří MAYER a Martin ČULEN. ROBUST ACUTE MYELOID LEUKEMIA ENGRAFTMENT IN HUMANIZED SCAFFOLDS USING INJECTABLE BIOMATERIALS AND INTRAVENOUS XENOTRANSPLANTATION. In III. ČESKÝ HEMATOLOGICKÝ A TRANSFUZIOLOGICKÝ SJEZD in Transfuze a Hematologie Dnes. 2024.

ČULEN, Martin; Daniel BUŠA; Zdeňka HERUDKOVÁ; Jan HÝL; Jakub VLAŽNÝ; Květoslava MATULOVÁ; Martin REPKO; Lucy VOJTOVÁ a Jiří MAYER. AML engraftment in humanized ossicles is not governed by biomaterial selection. In ESH: 4th Scientific Workshop: the Haematological Tumour Microenvironment and its Therapeutic Targeting, UK, Londýn. 2023.

ČULEN, Martin; Tomáš LOJA; Daniel BUŠA; Zdeňka HERUDKOVÁ; Jan HÝL; Jakub VLAŽNÝ; K. LIŠKOVÁ; Martin REPKO; Lucy VOJTOVÁ a Jiří MAYER. Biomaterial selection does not affect AML engraftment in humanized ossicles. In 12th International Conference Analytical Cytometry, Praha. 2023.

HÝL, Jan; Veronika BUČKOVÁ; Tereza SLAMĚNÍKOVÁ a Martin ČULEN. Effect of media components and feeder cells on in vitro culture of acute myeloid leukemia. In ESH: 6th International Conference: Acute Myeloid Leukemia "Molecular and Translational": Advances in Biology and Treatment, Estoril, Portugalsko. 2023.

LADUNGOVÁ, Adriana; Daniel BUŠA; Yusuf LODHI; Jan HÝL; Martin ČULEN a Michal ŠMÍDA. Identificationof novel therapeutic options for venetoclax-resistant AML cells through drug repurposing. In 23. Pražské hematologické dny, Praha. 2023.

LADUNGOVÁ, Adriana; Daniel BUŠA; Yusuf LODHI; Jan HÝL; Martin ČULEN a Michal ŠMÍDA. . Drug repurposing for venetoclax-resistant acute myeloid leukemia. In PhD retreat 2022, Telč. 2022.

LADUNGOVÁ, Adriana; Daniel BUŠA; Yusuf LODHI; Jan HÝL; Martin ČULEN a Michal ŠMÍDA. Identification of novel therapeutic options for venetoclax-resistant AML cells through drug repurposing. In EHA 2022 in HemaSphere 2022; 6(S3): 626-627. 2022.

LADUNGOVÁ, Adriana; Daniel BUŠA; Yusuf LODHI; Jan HÝL; Martin ČULEN a Michal ŠMÍDA. Prediction of novel treatment options for venetoclax-resistant AML cells based on drug repurposing. In Functional Precision Medicine for Blood Cancer Workshop and Symposium, Helsinki, Finland. 2022.